Related Experiment Video

Updated: Aug 18, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

Treatment of patent ductus arteriosus

Jonathan Wyllie1

  • 1The James Cook University Hospital, Marton Road, Middlesbrough TS4 3BW, UK. Johathan.Wyllie@stees.nhs.uk

Seminars in Neonatology : SN
|March 6, 2004
PubMed

Insights

Patent ductus arteriosus (PDA) is common in premature infants. While treatments exist, optimal timing and diagnostic criteria for intervention remain debated, risking unnecessary treatment in many cases.

Area of Science:

  • Neonatal Medicine
  • Pediatric Cardiology

Background:

  • Patent ductus arteriosus (PDA) is a frequent complication in premature infants, with incidence inversely proportional to gestational age.
  • Factors like antenatal steroids, fluid management, and phototherapy may influence PDA incidence.
  • Significant controversy exists regarding the indications for PDA treatment, ranging from prophylactic measures to intervention only for demonstrably significant cases.

Purpose of the Study:

  • To review the current understanding and controversies surrounding the diagnosis and management of PDA in premature infants.
  • To highlight the challenges in determining appropriate treatment indications and timing for PDA.

Main Methods:

  • Literature review of studies on PDA in premature infants.
  • Analysis of diagnostic criteria for PDA patency and significance.
  • Discussion of current treatment strategies, including medical and surgical interventions.

Main Results:

  • Prophylactic treatment may lead to unnecessary treatment in up to 64% of infants.
  • Accurate diagnosis is crucial for timely treatment of significant or symptomatic PDA.
  • Medical closure is preferred, with surgery reserved for refractory cases or contraindications.

Conclusions:

  • The optimal timing for PDA intervention remains undetermined.
  • Standardized diagnostic criteria and evidence-based treatment guidelines are needed.
  • Further research is required to resolve controversies in PDA management.

More Related Videos

Closure of a Patent Foramen Ovale (PFO): An Intervention Sequence10:52

Closure of a Patent Foramen Ovale (PFO): An Intervention Sequence

Published on: December 23, 2022

Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography09:31

Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography

Published on: January 27, 2023

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Mitral Stenosis IV: Nursing Management01:27

Mitral Stenosis IV: Nursing Management

A comprehensive nursing assessment is essential for patients with valvular heart disease, which involves any dysfunction of the heart valves that could impact blood flow and overall heart function.Subjective Data Collection:Chief Complaint and Present Illness: Start with the patient's primary concerns, focusing on the onset, duration, and progression of cardiac symptoms such as dyspnea, fatigue, chest pain, and palpitations.Past Medical History: Collect detailed information on any previous...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...